Respiratory diseases represent the most prevalent class of diseases in the Russian Federation, accounting for up to 25.0% of the total morbidity structure according to various authors. Several authors suggest that the proportion of patients with chronic obstructive pulmonary disease (COPD) with emphysema has increased in recent years. One of the reasons for the rising prevalence of emphysema is the aftermath of COVID‑19. The aim of this study is to analyze the changes in the incidence of emphysema before, during, and after the COVID‑19 pandemic. Materials and methods. The study included the results of chest computed tomography (CT) scans processed using artificial intelligencebased software, enabling the assessment of the volume of emphysematous lung tissue damage. Patient samples were divided into four periods: the «pre-COVID period» (625 studies), the «COVID period» (6,809 studies), the «post-COVID2023» period (101,872 studies), and the «post-COVID2024» period (78,539 studies). Results. The proportion of studies indicating emphysema in the pre-COVID period was 5.60%, increasing to 9.37% during the COVID period, and then decreasing to 6.63% in the first post-COVID year (2023), with a subsequent increase to 7.67% in the second post-COVID year (2024). Statistically significant differences in the percentage of emphysema were found in 2022, 2023, and 2024 when analyzed pairwise. Notably, when categorized by the severity of the disease, significant emphysema (>6% lung involvement) was more prevalent in 2024, with an average percentage of 25.79% in this group. Conclusion. Our study confirms a significant increase in cases of emphysema in the population in recent years, which may be associated with the impact of the COVID‑19 pandemic. The proportion of patients with signs of emphysema in 2024 was 7.67%, which is 1% higher than in 2023.